Is Sjögren's Syndrome Associated With Meibomian Gland Dysfunction ?

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-05-01

Study Completion Date

2017-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators hypothesize that the dry eye caused by SS may include the evaporative type, resulting from the MGD. Furthermore, the investigators hypothesize that both pSS and sSS are associated with MGD.To test our hypothesis, we conducted a prospective clinical study in patients with SS (both pSS and sSS) and MGD, and the normal population All subjects were matched for both age and gender and assessed for tear function and ocular surface signs and symptoms.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Sjögren's Syndrome Is Associated With Meibomian Gland Dysfunction

NCT03434106

Meibomian Gland Dysfunction Sjögren's Syndrome

UNKNOWN NA

A Randomized, Parallel-Group Comparison Study of Topical Corticosteroids in Dry Eye Patients With Sjögren Syndrome

NCT02011776

Dry Eye Syndromes Sjögren Syndrome

COMPLETED

Mycophenolate Sodium Treatment in Patients With Primary Sjogren's Syndrome

NCT00542763

Primary Sjogren's Syndrome

COMPLETED PHASE1

AST Combined With 0.05% Cyclosporin Eye Drop Improve Corneal Nerve Density in Patients With SS Dry Eye

NCT06013436

Sjogren's Syndrome Dry Eye Ocular Surface Disease

COMPLETED

Comparing Effect of Topical Tacrolimus 0.03% Versus Cyclosporine 0.05% in Dry Eyes of Secondary Sjogren Syndrome

NCT03865888

Dry Eye Sjogren Syndrome

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sjögren's Syndrome Meibomian Gland Dysfunction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

primary Sjögren's syndrome

The female patients with primary Sjögren's syndrome receive the Tears Naturale Forte and Liposic.

Group Type EXPERIMENTAL

Tears Naturale Forte

Intervention Type DRUG

This medication is used to relieve dry, irritated eyes

liposic

Intervention Type DRUG

Liposic eye gel contain the active ingredient carbomer, which is a type of medicine known as an eye lubricant. It is used for the treatment of the symptoms of dry eye.

secondary Sjögren's syndrome

The female patients with secondary Sjögren's syndrome receive Tears Naturale Forte and Liposic.

Group Type EXPERIMENTAL

Tears Naturale Forte

Intervention Type DRUG

This medication is used to relieve dry, irritated eyes

liposic

Intervention Type DRUG

Liposic eye gel contain the active ingredient carbomer, which is a type of medicine known as an eye lubricant. It is used for the treatment of the symptoms of dry eye.

meibomian gland dysfunction

The female patients with meibomian gland dysfunction receive the Tears Naturale Forte and Liposic.

Group Type EXPERIMENTAL

Tears Naturale Forte

Intervention Type DRUG

This medication is used to relieve dry, irritated eyes

liposic

Intervention Type DRUG

Liposic eye gel contain the active ingredient carbomer, which is a type of medicine known as an eye lubricant. It is used for the treatment of the symptoms of dry eye.

control

the female had no history of autoimmune disease receive the Tears Naturale Forte and Liposic.

Group Type EXPERIMENTAL

Tears Naturale Forte

Intervention Type DRUG

This medication is used to relieve dry, irritated eyes

liposic

Intervention Type DRUG

Liposic eye gel contain the active ingredient carbomer, which is a type of medicine known as an eye lubricant. It is used for the treatment of the symptoms of dry eye.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tears Naturale Forte

This medication is used to relieve dry, irritated eyes

Intervention Type DRUG

liposic

Liposic eye gel contain the active ingredient carbomer, which is a type of medicine known as an eye lubricant. It is used for the treatment of the symptoms of dry eye.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

DEXTRAN/HYPROMELLOSE/GLYCERIN Carbomer

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All the subjects are female and age between 50-60 years
* Patients with primary SS fulfilled the criteria established by the European Study Group
* Patients with SLE and RA met the criteria set by the American College of Rheumatology